The estimated Net Worth of Jay R. Luly is at least $26 millió dollars as of 5 December 2023. Jay Luly owns over 7,230 units of Enanta Pharmaceuticals Inc stock worth over $9,713,788 and over the last 11 years he sold ENTA stock worth over $11,827,510. In addition, he makes $4,483,500 as President, Chief Executive Officer és Director at Enanta Pharmaceuticals Inc.
Sign up
Jay Luly ENTA stock SEC Form 4 insiders trading
Jay has made over 28 trades of the Enanta Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 7,230 units of ENTA stock worth $69,625 on 5 December 2023.
The largest trade he's ever made was exercising 251,119 units of Enanta Pharmaceuticals Inc stock on 10 January 2014 worth over $183,317. On average, Jay trades about 13,634 units every 64 days since 2013. As of 5 December 2023 he still owns at least 806,793 units of Enanta Pharmaceuticals Inc stock.
You can see the complete history of Jay Luly stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jay Luly biography
Dr. Jay R. Luly, Ph.D. is President, Chief Executive Officer, Director of the company. Prior to joining Enanta, Dr. Luly was an Entrepreneur in Residence at Oxford Bioscience Partners. Before joining Oxford in March 2002, Dr. Luly held the positions of Senior Vice President, Research and Development Operations and Senior Vice President, Discovery Strategy and Operations at Millennium Pharmaceuticals following Millennium’s merger with LeukoSite, Inc., where he had served as Senior Vice President, Drug Discovery and Preclinical Development. Prior to joining LeukoSite, he held a number of senior drug discovery positions at Abbott Laboratories from 1983 to 1997. Dr. Luly received a B.S. from the University of Illinois, Urbana/Champaign and a Ph.D. in synthetic organic chemistry from the University of California, Berkeley.
What is the salary of Jay Luly?
As the President, Chief Executive Officer és Director of Enanta Pharmaceuticals Inc, the total compensation of Jay Luly at Enanta Pharmaceuticals Inc is $4,483,500. There are no executives at Enanta Pharmaceuticals Inc getting paid more.
How old is Jay Luly?
Jay Luly is 63, he's been the President, Chief Executive Officer és Director of Enanta Pharmaceuticals Inc since 2003. There are 8 older and 6 younger executives at Enanta Pharmaceuticals Inc. The oldest executive at Enanta Pharmaceuticals Inc is Bruce Carter, 76, who is the Independent Non-Executive Chairman of the Board.
What's Jay Luly's mailing address?
Jay's mailing address filed with the SEC is C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN, MA, 02472.
Insiders trading at Enanta Pharmaceuticals Inc
Over the last 12 years, insiders at Enanta Pharmaceuticals Inc have traded over $72,640,961 worth of Enanta Pharmaceuticals Inc stock and bought 354,891 units worth $5,071,651 . The most active insiders traders include Jay R. Luly, V Life Science Ventures Gmb... és Yat Sun Or. On average, Enanta Pharmaceuticals Inc executives and independent directors trade stock every 26 days with the average trade being worth of $285,155. The most recent stock trade was executed by Scott T. Rottinghaus on 11 July 2024, trading 11,945 units of ENTA stock currently worth $190,762.
What does Enanta Pharmaceuticals Inc do?
enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta’s lead protease inhibitor, paritaprevir, is part of abbvie’s recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.
What does Enanta Pharmaceuticals Inc's logo look like?
Complete history of Jay Luly stock trades at Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals Inc executives and stock owners
Enanta Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Jay Luly,
President, Chief Executive Officer, Director -
Yat Sun Or,
Senior Vice President - Research & Development, Chief Scientific Officer -
Nathalie Adda,
Senior Vice President and Chief Medical Officer -
Paul Mellett,
Chief Financial Officer, Senior Vice President - Finance & Administration -
Nathaniel Gardiner,
Senior Vice President, General Counsel -
Dr. Jay R. Luly,
Pres, CEO & Director -
Dr. Yat Sun Or,
Sr. VP of R&D and Chief Scientific Officer -
Dr. Nathalie Adda,
Sr. VP & Chief Medical Officer -
Nathaniel S. Gardiner J.D.,
Sr. VP, Gen. Counsel & Sec. -
Paul J. Mellett Jr.,
Sr. VP of Fin. & Admin. and CFO -
Bruce Carter,
Independent Non-Executive Chairman of the Board -
Terry Vance,
Independent Director -
George Golumbeski,
Independent Director -
Lesley Russell,
Independent Director -
Kristine Peterson,
Independent Director -
Mark Foletta,
Independent Director -
Carol Miceli,
Director, Investor Relations -
Brendan Luu,
Sr. VP of Bus. Devel. -
Tara Lynn Kieffer Ph.D.,
Sr. VP of New Product Strategy & Devel. -
Jennifer Viera,
Sr. Director of Investor Relations & Corp. Communications -
Ernst Guenter Afting,
Director -
Tim Ocain,
Senior Vice President -
Stephen Jr. Buckley,
Director -
V Life Science Ventures Gmb...,
-
V Life Science Ventures Gmb...,
-
Helmut Schuhsler,
Director -
David Poorvin,
Director -
Capital Granite, L.P.M Rna ...,
-
Marc E. Goldberg,
Director -
Gregory L. Verdine,
Director -
& Co Ltd Shionogi,
10% owner -
Yujiro S Hata,
Director -
Brendan Luu,
Chief Business Officer -
Scott T. Rottinghaus,
Chief Medical Officer -
Tara Lynn Kieffer,
Chief Product Strategy Officer -
Matthew Paul Kowalsky,
Chief Legal Officer